4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

Corporate Overview for Investors February 2026 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Synopsys, Inc.'s (Synopsys, we or our) short-term and long-term financial targets, expectations and objectives; our businesses, business segments, strategies, partnerships, initiatives and opportunities, including, among other things, the reallocation of resources in our Design IP segment to higher growth opportunities and planne ...

Investor Presentation Fourth Quarter 2025 Legal Disclaimer FORWARD-LOOKING STATEMENTS. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, references to: potential or expected future cash flows; estimated or expected returns, sometimes referred to as initial IRR, updated IRR, expected IRR, or current-to-maturity IRR; potential discount rates; potential future investments; e ...

Q4'25 Supplemental Presentation Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or future financial or operating performance. In some cases, you can identify forward-looking statements by terminology ...

February 25, 2026 4Q and FY25 EARNINGS PRESENTATION 4Q25 EARNNINGS PRESENTATION 0 4Q25 EARNNINGS PRESENTATION DISCLAIMER FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology or product developments, financing and investment ...

Q4 & FY 2025 Earnings Update February 25, 2026 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook, business strategy, and growth initiatives. These statements involve risks and uncertainties that could cause actual results to differ materially. We undertake no obligation to update forward-looking statements except as required by law. Please refer to o ...

Full Year 2025 Investor Presentation Oncology and Immunology Portfolio Summary February 25, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including, without l ...

Fourth Quarter and Full Year 2025 Earnings Call February 25, 2026 Call Agenda Catherine Owen Adams Chief Executive Officer Welcome Commercial Update Tom Garner Executive Vice President, Chief Commercial Officer Elizabeth H.Z. Thompson, Ph.D. Executive Vice President, Head of Research and Development R&D Update Financial Update Mark Schneyer Executive Vice President, Chief Financial Officer Al Kildani Senior Vice President, IR and Corporate Communications CEO Opening Remarks Closing Remarks Catherine Owen Ad ...

Financial Highlights Q4 2025 February 25, 2026 Magnite SÿĄă HÿrĀor FORWARD-LOOKING STATEMENTS This presentation and management's prepared remarks during the conference call discussing fourth quarter 2025 results include, and management's answers to questions during the conference call may include, forward-looking statements, including statements based upon or relating to our expectations, assumptions, estimates, and projections. In some cases, you can identify forward-looking statements by terms such as "ma ...

Q2 FY2026 Earnings February 25, 2026 To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, this presentation includes the following non-GAAP financial and other key performance measures: non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income per share (diluted), free cash flow, Annual Recurring Revenue (or ARR), and Average Contract Duration. In computing non-GAAP financial measure ...